Journal article

Development of neuropathy in patients with myeloma treated with thalidomide: Patterns of occurrence and the role of electrophysiologic monitoring

Linda Mileshkin, Richard Stark, Bruce Day, John F Seymour, Jerome B Zeldis, H Miles Prince

JOURNAL OF CLINICAL ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2006

Abstract

PURPOSE: Peripheral neuropathy frequently limits the duration of treatment with thalidomide for patients with multiple myeloma. We assessed the time course of occurrence, possible predictive factors, and the utility of serial nerve electrophysiological studies (NES) for detecting onset of neuropathy. PATIENTS AND METHODS: Seventy-five patients with relapsed/refractory myeloma were enrolled onto a multicenter trial of dose-escalating thalidomide with or without interferon. Patients underwent clinical assessment plus NES at baseline and every 3 months. Time to development of neuropathy according to clinical or NES criteria was compared. Patient and treatment-related factors were compared as pr..

View full abstract